Mouse Anti-VEGFA Recombinant Antibody (clone MV833) (CAT#: HPAB-S0148-YC)

Figure 1 Inhibition of tumor-induced angiogenesis by MV833.

Three i.v. administrations of MV833 (100 µg) suppressed the neovascularization induced by HT-1080 cells to the level of the control (no tumor cells). These results indicated that MV833 neutralized the activity of VEGF secreted from tumor cells and inhibited tumor-induced neovascularization in vivo.

Asano, M., Yukita, A., & Suzuki, H. (1999). Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Japanese journal of cancer research, 90(1), 93-100.

Figure 2 The tumor growth of two HeLa cell lines and its inhibition by MV833 in vivo.

The growth of both HeLa/v5 and HeLa/c tumors was almost completely suppressed by the administration of MV833.

Asano, M., Yukita, A., & Suzuki, H. (1999). Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Japanese journal of cancer research, 90(1), 93-100.

Figure 3 Inhibitory effect of MV833 on the growth of human colon tumors in vivo.

The growth of five of these colon tumors was markedly suppressed by MV833.

Asano, M., Yukita, A., & Suzuki, H. (1999). Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Japanese journal of cancer research, 90(1), 93-100.

Figure 4 Inhibition of advanced growing tumor by MV833 in vivo.

In some tumor lines, treatment with MV833 was delayed until the tumor volume had reached 400-500^mm3; almost complete suppression was observed after the treatment.

Asano, M., Yukita, A., & Suzuki, H. (1999). Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Japanese journal of cancer research, 90(1), 93-100.